Systemic AL (λ) Amyloidosis Discovered After Neoadjuvant Pembrolizumab‐Based Chemoimmunotherapy for Resectable NSCLC: Case Report
Weijie Ma, Dana M. Ferrari‐Light, Liang Lu · 2026
Read Systemic AL (λ) Amyloidosis Discovered After Neoadjuvant Pembrolizumab‐Based Chemoimmunotherapy for Resectable NSCLC: Case Report by Weijie Ma, Dana M. Ferrari‐Light, Liang Lu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13087107.txt.
Description
Protein deposits throughout the body were found by surprise in a lung cancer patient after strong immune drug treatment, in this 2026 case report by Weijie Ma and co-authors. The patient was a sixty-nine-year-old man with a resectable lung tumor in the right upper lobe. He received an immune drug plus chemotherapy before surgery.
Surgery removed the lobe, and half the tumor in the removed tissue was still alive, with clear margins and no spread to lymph nodes. Tumor tests showed a very high level of a marker that predicts immune drug response. Alongside the treatment effect, tissue staining revealed widespread deposits of the faulty protein. Such deposits are rarely reported alongside immune drug use, and the case urges doctors to watch for them.
Catalog record
| CREATOR | Weijie Ma, Dana M. Ferrari‐Light, Liang Lu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |